Exact Sciences (EXAS) Competitors $43.67 -0.58 (-1.31%) Closing price 04:00 PM EasternExtended Trading$43.20 -0.47 (-1.06%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EXAS vs. ALNY, BIIB, UTHR, INCY, BMRN, EXEL, NBIX, HALO, MDGL, and RGENShould you be buying Exact Sciences stock or one of its competitors? The main competitors of Exact Sciences include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), and Repligen (RGEN). These companies are all part of the "biotechnology" industry. Exact Sciences vs. Alnylam Pharmaceuticals Biogen United Therapeutics Incyte BioMarin Pharmaceutical Exelixis Neurocrine Biosciences Halozyme Therapeutics Madrigal Pharmaceuticals Repligen Exact Sciences (NASDAQ:EXAS) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, community ranking, dividends, risk and profitability. Do analysts rate EXAS or ALNY? Exact Sciences presently has a consensus target price of $69.25, suggesting a potential upside of 58.58%. Alnylam Pharmaceuticals has a consensus target price of $315.58, suggesting a potential upside of 36.66%. Given Exact Sciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Exact Sciences is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exact Sciences 0 Sell rating(s) 2 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.95Alnylam Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 21 Buy rating(s) 0 Strong Buy rating(s) 2.77 Which has more volatility and risk, EXAS or ALNY? Exact Sciences has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Which has stronger earnings & valuation, EXAS or ALNY? Exact Sciences has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Exact Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExact Sciences$2.76B2.94-$204.15M-$5.57-7.84Alnylam Pharmaceuticals$2.25B13.36-$278.16M-$2.17-106.42 Is EXAS or ALNY more profitable? Alnylam Pharmaceuticals has a net margin of -12.37% compared to Exact Sciences' net margin of -37.29%. Alnylam Pharmaceuticals' return on equity of 0.00% beat Exact Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Exact Sciences-37.29% -5.29% -2.45% Alnylam Pharmaceuticals -12.37%N/A -6.83% Does the MarketBeat Community prefer EXAS or ALNY? Alnylam Pharmaceuticals received 172 more outperform votes than Exact Sciences when rated by MarketBeat users. Likewise, 76.31% of users gave Alnylam Pharmaceuticals an outperform vote while only 73.14% of users gave Exact Sciences an outperform vote. CompanyUnderperformOutperformExact SciencesOutperform Votes99173.14% Underperform Votes36426.86% Alnylam PharmaceuticalsOutperform Votes116376.31% Underperform Votes36123.69% Does the media prefer EXAS or ALNY? In the previous week, Exact Sciences had 6 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 30 mentions for Exact Sciences and 24 mentions for Alnylam Pharmaceuticals. Exact Sciences' average media sentiment score of 0.88 beat Alnylam Pharmaceuticals' score of 0.84 indicating that Exact Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exact Sciences 10 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 13 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in EXAS or ALNY? 88.8% of Exact Sciences shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 1.4% of Exact Sciences shares are owned by insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryExact Sciences beats Alnylam Pharmaceuticals on 10 of the 19 factors compared between the two stocks. Remove Ads Get Exact Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXAS vs. The Competition Export to ExcelMetricExact SciencesMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.11B$2.86B$5.33B$7.57BDividend YieldN/A31.37%5.11%4.33%P/E Ratio-7.8413.3521.7317.81Price / Sales2.94187.25379.1494.58Price / Cash8.7957.5638.1534.64Price / Book3.384.556.464.00Net Income-$204.15M-$22.21M$3.20B$247.23M7 Day Performance8.34%7.36%6.54%7.26%1 Month Performance-2.96%-1.18%-8.55%-6.26%1 Year Performance-33.18%6.31%10.33%-0.18% Exact Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXASExact Sciences4.2259 of 5 stars$43.67-1.3%$69.25+58.6%-38.0%$8.11B$2.76B-7.846,400ALNYAlnylam Pharmaceuticals4.507 of 5 stars$232.95-1.2%$316.25+35.8%+61.6%$30.30B$2.25B-107.352,000BIIBBiogen4.6943 of 5 stars$119.19-3.1%$213.33+79.0%-39.8%$17.45B$9.68B10.658,720Analyst RevisionUTHRUnited Therapeutics4.9019 of 5 stars$291.72-0.3%$388.25+33.1%+22.2%$13.10B$2.88B12.81980Insider TradeNews CoveragePositive NewsGap DownINCYIncyte4.8613 of 5 stars$60.29-0.5%$74.88+24.2%+10.0%$11.67B$4.24B223.302,320BMRNBioMarin Pharmaceutical4.887 of 5 stars$59.16-1.8%$94.00+58.9%-35.3%$11.29B$2.85B26.893,401Positive NewsHigh Trading VolumeEXELExelixis4.2548 of 5 stars$34.84+0.8%$37.59+7.9%+56.7%$9.75B$2.17B19.681,220Positive NewsGap DownNBIXNeurocrine Biosciences4.8388 of 5 stars$93.25-2.5%$163.52+75.4%-29.5%$9.30B$2.36B28.341,200Analyst UpgradeNews CoveragePositive NewsGap UpHigh Trading VolumeHALOHalozyme Therapeutics4.3932 of 5 stars$59.35-0.7%$62.78+5.8%+59.0%$7.33B$1.02B17.30390Positive NewsMDGLMadrigal Pharmaceuticals4.0481 of 5 stars$310.52-1.2%$378.44+21.9%+36.2%$6.86B$180.13M-12.3890News CoveragePositive NewsRGENRepligen4.7422 of 5 stars$116.11+3.7%$178.64+53.9%-25.8%$6.52B$634.44M-227.672,020Positive NewsGap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Alnylam Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives Incyte Alternatives BioMarin Pharmaceutical Alternatives Exelixis Alternatives Neurocrine Biosciences Alternatives Halozyme Therapeutics Alternatives Madrigal Pharmaceuticals Alternatives Repligen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXAS) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EXAS Stock Free EXAS Stock Alerts